Cargando…

Comprehensive Statistical Exploration of Prognostic (Bio-)Markers for Responses to Immune Checkpoint Inhibitor in Patients with Non-Small Cell Lung Cancer

SIMPLE SUMMARY: Metastatic non-small cell lung cancer (NSCLC) patients treated with immune checkpoint inhibitors (ICIs) may suffer from heavy side effects, and not all patients benefit from the treatment. Therefore, it is crucial to gain knowledge about possible (bio-)markers for response to ICIs. W...

Descripción completa

Detalles Bibliográficos
Autores principales: Hiltbrunner, Stefanie, Spohn, Meta-Lina, Wechsler, Ramona, Akhoundova, Dilara, Bankel, Lorenz, Kasser, Sabrina, Bihr, Svenja, Britschgi, Christian, Maathuis, Marloes H., Curioni-Fontecedro, Alessandra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8750624/
https://www.ncbi.nlm.nih.gov/pubmed/35008239
http://dx.doi.org/10.3390/cancers14010075
_version_ 1784631502726758400
author Hiltbrunner, Stefanie
Spohn, Meta-Lina
Wechsler, Ramona
Akhoundova, Dilara
Bankel, Lorenz
Kasser, Sabrina
Bihr, Svenja
Britschgi, Christian
Maathuis, Marloes H.
Curioni-Fontecedro, Alessandra
author_facet Hiltbrunner, Stefanie
Spohn, Meta-Lina
Wechsler, Ramona
Akhoundova, Dilara
Bankel, Lorenz
Kasser, Sabrina
Bihr, Svenja
Britschgi, Christian
Maathuis, Marloes H.
Curioni-Fontecedro, Alessandra
author_sort Hiltbrunner, Stefanie
collection PubMed
description SIMPLE SUMMARY: Metastatic non-small cell lung cancer (NSCLC) patients treated with immune checkpoint inhibitors (ICIs) may suffer from heavy side effects, and not all patients benefit from the treatment. Therefore, it is crucial to gain knowledge about possible (bio-)markers for response to ICIs. We used retrospective data acquired from NSCLC patients treated with ICIs in first- or further-line therapy settings, including 16 possible markers. We conducted a comprehensive statistical analysis study to find markers for response to treatment, assessed the robustness of our results, and discussed often encountered statistical pitfalls. Our study yielded hypotheses for various predictive and prognostic (bio-)markers for response to ICIs in NSCLC patients. In particular, we found that high basophil counts may be predictive for treatment response in patients in further-line therapy settings. ABSTRACT: Metastatic non-small cell lung cancer (NSCLC) patients treated with immune checkpoint inhibitors (ICIs) may suffer from heavy side effects and not all patients benefit from the treatment. We conducted a comprehensive statistical analysis to identify promising (bio-)markers for treatment response. We analyzed retrospective data from NSCLC patients treated with ICIs in first- or further-line therapy settings at the University Hospital Zurich. We investigated 16 possible prognostic markers with respect to overall survival, tumor size reduction, and the development of an immune-related adverse event (irAE) and assessed the robustness of our results. For the further-line patient group, the most significant result was that increased basophil counts were associated with increased odds of tumor size reduction within three months and with the development of an irAE. For the first-line patient group, the most significant results were that increased lymphocyte counts, the histology of adenocarcinoma, and the intake of non-steroidal anti-rheumatic drugs (NSAR) were associated with decreased hazards of dying. Our study yielded new hypotheses for predictive (bio-)markers for response to ICIs in NSCLC patients. The possibly beneficial role of high basophil counts is a particularly interesting finding. Our results should be tested on independent data in a prospective fashion.
format Online
Article
Text
id pubmed-8750624
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-87506242022-01-12 Comprehensive Statistical Exploration of Prognostic (Bio-)Markers for Responses to Immune Checkpoint Inhibitor in Patients with Non-Small Cell Lung Cancer Hiltbrunner, Stefanie Spohn, Meta-Lina Wechsler, Ramona Akhoundova, Dilara Bankel, Lorenz Kasser, Sabrina Bihr, Svenja Britschgi, Christian Maathuis, Marloes H. Curioni-Fontecedro, Alessandra Cancers (Basel) Article SIMPLE SUMMARY: Metastatic non-small cell lung cancer (NSCLC) patients treated with immune checkpoint inhibitors (ICIs) may suffer from heavy side effects, and not all patients benefit from the treatment. Therefore, it is crucial to gain knowledge about possible (bio-)markers for response to ICIs. We used retrospective data acquired from NSCLC patients treated with ICIs in first- or further-line therapy settings, including 16 possible markers. We conducted a comprehensive statistical analysis study to find markers for response to treatment, assessed the robustness of our results, and discussed often encountered statistical pitfalls. Our study yielded hypotheses for various predictive and prognostic (bio-)markers for response to ICIs in NSCLC patients. In particular, we found that high basophil counts may be predictive for treatment response in patients in further-line therapy settings. ABSTRACT: Metastatic non-small cell lung cancer (NSCLC) patients treated with immune checkpoint inhibitors (ICIs) may suffer from heavy side effects and not all patients benefit from the treatment. We conducted a comprehensive statistical analysis to identify promising (bio-)markers for treatment response. We analyzed retrospective data from NSCLC patients treated with ICIs in first- or further-line therapy settings at the University Hospital Zurich. We investigated 16 possible prognostic markers with respect to overall survival, tumor size reduction, and the development of an immune-related adverse event (irAE) and assessed the robustness of our results. For the further-line patient group, the most significant result was that increased basophil counts were associated with increased odds of tumor size reduction within three months and with the development of an irAE. For the first-line patient group, the most significant results were that increased lymphocyte counts, the histology of adenocarcinoma, and the intake of non-steroidal anti-rheumatic drugs (NSAR) were associated with decreased hazards of dying. Our study yielded new hypotheses for predictive (bio-)markers for response to ICIs in NSCLC patients. The possibly beneficial role of high basophil counts is a particularly interesting finding. Our results should be tested on independent data in a prospective fashion. MDPI 2021-12-24 /pmc/articles/PMC8750624/ /pubmed/35008239 http://dx.doi.org/10.3390/cancers14010075 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Hiltbrunner, Stefanie
Spohn, Meta-Lina
Wechsler, Ramona
Akhoundova, Dilara
Bankel, Lorenz
Kasser, Sabrina
Bihr, Svenja
Britschgi, Christian
Maathuis, Marloes H.
Curioni-Fontecedro, Alessandra
Comprehensive Statistical Exploration of Prognostic (Bio-)Markers for Responses to Immune Checkpoint Inhibitor in Patients with Non-Small Cell Lung Cancer
title Comprehensive Statistical Exploration of Prognostic (Bio-)Markers for Responses to Immune Checkpoint Inhibitor in Patients with Non-Small Cell Lung Cancer
title_full Comprehensive Statistical Exploration of Prognostic (Bio-)Markers for Responses to Immune Checkpoint Inhibitor in Patients with Non-Small Cell Lung Cancer
title_fullStr Comprehensive Statistical Exploration of Prognostic (Bio-)Markers for Responses to Immune Checkpoint Inhibitor in Patients with Non-Small Cell Lung Cancer
title_full_unstemmed Comprehensive Statistical Exploration of Prognostic (Bio-)Markers for Responses to Immune Checkpoint Inhibitor in Patients with Non-Small Cell Lung Cancer
title_short Comprehensive Statistical Exploration of Prognostic (Bio-)Markers for Responses to Immune Checkpoint Inhibitor in Patients with Non-Small Cell Lung Cancer
title_sort comprehensive statistical exploration of prognostic (bio-)markers for responses to immune checkpoint inhibitor in patients with non-small cell lung cancer
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8750624/
https://www.ncbi.nlm.nih.gov/pubmed/35008239
http://dx.doi.org/10.3390/cancers14010075
work_keys_str_mv AT hiltbrunnerstefanie comprehensivestatisticalexplorationofprognosticbiomarkersforresponsestoimmunecheckpointinhibitorinpatientswithnonsmallcelllungcancer
AT spohnmetalina comprehensivestatisticalexplorationofprognosticbiomarkersforresponsestoimmunecheckpointinhibitorinpatientswithnonsmallcelllungcancer
AT wechslerramona comprehensivestatisticalexplorationofprognosticbiomarkersforresponsestoimmunecheckpointinhibitorinpatientswithnonsmallcelllungcancer
AT akhoundovadilara comprehensivestatisticalexplorationofprognosticbiomarkersforresponsestoimmunecheckpointinhibitorinpatientswithnonsmallcelllungcancer
AT bankellorenz comprehensivestatisticalexplorationofprognosticbiomarkersforresponsestoimmunecheckpointinhibitorinpatientswithnonsmallcelllungcancer
AT kassersabrina comprehensivestatisticalexplorationofprognosticbiomarkersforresponsestoimmunecheckpointinhibitorinpatientswithnonsmallcelllungcancer
AT bihrsvenja comprehensivestatisticalexplorationofprognosticbiomarkersforresponsestoimmunecheckpointinhibitorinpatientswithnonsmallcelllungcancer
AT britschgichristian comprehensivestatisticalexplorationofprognosticbiomarkersforresponsestoimmunecheckpointinhibitorinpatientswithnonsmallcelllungcancer
AT maathuismarloesh comprehensivestatisticalexplorationofprognosticbiomarkersforresponsestoimmunecheckpointinhibitorinpatientswithnonsmallcelllungcancer
AT curionifontecedroalessandra comprehensivestatisticalexplorationofprognosticbiomarkersforresponsestoimmunecheckpointinhibitorinpatientswithnonsmallcelllungcancer